Live feed02:03:00·6dPRReleasevia QuantisnowIMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapiesByQuantisnow·Wall Street's wire, on your screen.JNJ· Johnson & JohnsonHealth Care
